argenx SE Topline Phase 3 Data From ADAPT-SC Study Call Transcript
Good morning, everyone, and welcome to the argenx Phase III ADAPT-SC Trial Top Line Results Conference Call. (Operator Instructions). To follow the presentation, we ask that you navigate the slides as directed by argenx management. There will be a question-and-answer session to follow.
I would now like to introduce Beth DelGiacco, Vice President of Corporate Communications and Investor Relations at argenx.
Thank you, and good morning to everyone on the call. Earlier today, we issued a press release summarizing our positive Top Line Phase III ADAPT-Subcu Trial Results. The press release and the presentation for today's webcast can be found on our website.
On the call today are Tim Van Hauwermeiren, our Chief Executive Officer; and Keith Woods, our Chief Operating Officer. Wim Parys, our Chief Medical Officer, will also be available for the Q&A session following prepared remarks.
Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
